Release Date: December 24, 2025

Expiration Date: December 24, 2026

Activity Overview

This educational activity is an archive of the live presentation held on November 15, 2025.

For more information about this educational activity, the faculty, and disclosures, please click here.

Target Audience

This educational activity is directed toward medical oncologists, along with advanced practice providers, oncology nurses, and pharmacists who manage patients with lung cancers. Other health care professionals interested in the treatment of lung cancers are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Identify key clinical features and red flags of paraneoplastic LEMS
Apply guideline-recommended processes for diagnosing LEMS and evaluating patients for underlying malignancy
Initiate evidence-based treatment for LEMS and alignment with SCLC therapy
Manage treatment-related toxicities associated with LEMS and SCLC therapies

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

GET STARTED WITH THIS PROGRAM:

Create Account Already Registered? Login Here

Accreditation/Credit Designation

Physicians’ Education Resource^®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource^®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Catalyst Pharmaceuticals, Inc.

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

GET STARTED WITH THIS PROGRAM:

Related Content